Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda To Start Phase I For Antibody Neuropathic Pain Drug

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical subsidiary Takeda Bio plans to start a domestic Phase I trial for neuropathic pain antibody injection AMG403

You may also be interested in...



OTC Decisions In March: Lumify Single-Use, Aleve Arthritis-Grip Cap Labeling, And More Prilosec, Mucinex Copies

Total of CDER decisions during March on OTC applications was down from January and February and also were less substantial for the marketplace. After approving OTC switches in first two months, March decisions for newly available OTCs were limited to additional guaifenesin/pseudoephedrine and omeprazole products offered as private label/store brand alternatives to brands.

COVID-19 Magnifies US Need To Make Supplements Eligible For Pre-Tax Savings – NPA

NPA asks Congress to include supplements in legislation defining "medical expenses” covered by pre-tax health savings accounts. The trade group says industry would prefer supplements were included with OTC drugs in provision in recently passed COVID-19 relief legislation that changed pre-tax account rules.

COVID-19: ResMed Ramps Up CPAP, BPAP Manufacturing To Address Ventilator Shortage

ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage. 

UsernamePublicRestriction

Register

SC075067

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel